Form 4: Rapport Therapeutics Director Wendy Young Acquires 6,000 Shares
SEC Form 4 Filing
Director Wendy Young purchased 6,000 shares of Rapport Therapeutics at an average price of $10.2083 on March 12, 2025.
Summary
- On March 12, 2025, Wendy B. Young, a director of Rapport Therapeutics, acquired 6,000 shares of common stock.
- The shares were purchased at a weighted average price of $10.2083.
- The transactions occurred at prices ranging from $10.20 to $10.25.
- Following the transaction, Wendy Young directly owns 6,000 shares of Rapport Therapeutics.
Sentiment
Score: 6
Explanation: A director purchasing shares is generally a mildly positive signal, suggesting confidence in the company, but it's a single transaction and doesn't provide a comprehensive view.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates a director's recent purchase of company stock.
Stakeholder Impact
- The purchase could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/12/2025 | Date of transaction: Wendy Young purchased 6,000 shares of Rapport Therapeutics. |
| 03/13/2025 | Date of signature: Attorney-in-Fact Troy Ignelzi signed the Form 4 on behalf of Wendy Young. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.